This study was designed to assess the utility of CEA, CRP, serum albumin level, hemoglobin, and LDH as biomarkers of cancer risk (colon, lung, breast, and pancreatic cancer) in obese and/or diabetic patients, and to study correlations between these markers and the prognosis of cancer patients with associated type two diabetes at the onset of treatment. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.